Abstract
Health Economic Impact and Highlighted Clinical/Safety Outcomes in 300 Relapsing Multiple Sclerosis Patients Treated with Alemtuzumab in a Single MS Center (P10-6.004)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
